04.10.2023 • News

AmbioPharm Appoints Brian Gregg as CEO

Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.

Gregg joins AmbioPharm after a 32-year career at Bachem Americas, where he most recently held the position of chief operating officer. He holds an MBA from the San Diego State University, US, and a Bachelor of Arts degree in Chemistry from the US University of California at San Diego.

Juncai (Chris) Bai, Chairman of the Company, said: “We are excited to welcome Brian to our executive team. He has both the leadership experience and necessary background to be immediately effective in growing our business in the U.S. and globally, and we look forward to working with him as we continue to expand on our service offerings and global customer base.”

Source: AmbioPharm
Source: AmbioPharm

Company

Logo:

AmbioPharm, Inc.

1024 Dittman Court
SC 29842 North Augusta
US

Company contact







Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read